In In re Copaxone Consolidated Cases, the Federal Circuit affirmed the district court decision finding four patents directed to a specific dosing regimen for using COPAXONE® 40 mg/ml to treat patients ...
Teva Files Citizen Petition with the U.S. Food and Drug Administration (FDA) Regarding the Complexity of COPAXONE® (glatiramer acetate) Following the Agency's Guidance Teva includes new gene ...
Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
This dose of Copaxone allows three times a week subcutaneous administration as compared to the daily administration schedule for the currently available formulation (20 mg/mL). The lower frequency of ...
Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...
A year ago, the Food and Drug Administration quietly posted a public notice that it wanted to hire an independent lab to test a generic drug that it had already approved. FDA wanted to make sure the ...
NEW YORK (Reuters) - Teva Pharmaceutical Industries on Thursday lost a third patent for its top-selling multiple sclerosis treatment as U.S. patent officials ruled that Copaxone did not deserve legal ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
Teva Pharmaceutical Industries Ltd has lost a bid to force the U.S. Food and Drug Administration to regulate its blockbuster multiple sclerosis drug Copaxone as a biologic drug, which would have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results